A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Compare the PK of Two Oral Formulations of SMP-100 and to Evaluate the Effect of Food on the Bioavailability of SMP-100 Tablets in Normal Healthy Volunteers
Latest Information Update: 14 Mar 2022
Price :
$35 *
At a glance
- Drugs CSTI 300 (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacokinetics
- Sponsors Chengdu SciMount Pharmatech
- 10 Mar 2022 Status changed from recruiting to completed.
- 24 Nov 2021 Planned primary completion date changed from 27 Oct 2021 to 27 Dec 2021.
- 24 Nov 2021 Status changed from not yet recruiting to recruiting.